Insmed Incorporated
http://www.insmed.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Insmed Incorporated
Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’
The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.
Who’s Hired? Lupin Appoints CEO To New API CDMO Subsidiary
Lupin has selected a CEO to lead its fresh API CDMO business venture, while the UK’s off-patent group BGMA has appointed a new vice-chair. Meanwhile, ChemWerth has welcomed a familiar face as its new president and Coherus has elected a new board member with a focus on immuno-oncology.
Finance Watch: Big Money In Post-Data Follow-On Offerings
Public Company Edition: Insmed grossed $650m, Structure raised $476m and Merus brought in $400.2m after positive clinical trial results. But while CARGO raised $110m in a private placement and Day One sold a priority review voucher for $108m, Ikena, Takeda and others cut jobs.
Insmed Planning 2025 Launch For Brensocatib In Bronchiectasis
The drug maker anticipates a smooth regulatory path and has already begun to rapidly expand its sales force across most of the US.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Pulmonary
- Site Specific
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Liposomes
- Other Names / Subsidiaries
-
- Insmed, Inc.
- Transave Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice